Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III vitiligo study of SCENESSE with NB-UVB
PACTR202405869934666Phase 3Not yet recruiting
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Oct 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of Afamelanotide and narrowband ultraviolet B in generalized vitiligo (2 arms), sponsored by Clinuvel Pharmaceuticals. Primary endpoint: T-VASI50 at Day 140. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
Afamelanotidenarrowband ultraviolet B
03
Conditions
generalized vitiligo
Beyond the preview
Go deeper on PACTR202405869934666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202405869934666.